Skip to main content
Smart Investors Daily
DN

AMEX · DNL

WisdomTree Global ex-U.S. Quality Dividend Growth Fund

Financial Services · Asset Management - Global

$43.94

Up+$0.32 (+0.74%)

Updated Oct 28, 2026, 11:31 AM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
480.63M
P/E ratio
—
Dividend yield
1.91%
52-week range
$38.87 – $47.46
Volume
19.1K
Avg. volume
68.78K

Price performance · DNL

DNL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 27, 2026

DNL closed at $43.94 after 21 trading sessions, down 2.06% for the selected period.

Last close
$43.94
Period change
-2.06%
Period low
$43.54
Period high
$45.61
Daily close
View OHLC price history
DNL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 27, 2026$43.8689$44.0085$43.76$43.93519.1K
Oct 26, 2026$43.56$43.80$43.531$43.608116.05K
Oct 23, 2026$43.30$43.6785$43.30$43.53627.16K
Oct 22, 2026$43.88$43.88$43.59$43.650813.85K
Oct 21, 2026$44.68$44.81$44.5621$44.677914.35K
Oct 20, 2026$44.24$44.685$44.24$44.552911.63K
Oct 19, 2026$44.37$44.48$44.22$44.2916.78K
Oct 16, 2026$44.76$44.7999$44.11$44.1112.19K
Oct 15, 2026$44.16$44.64$44.01$44.621821.12K
Oct 14, 2026$44.68$44.815$44.365$44.425711.3K
Oct 13, 2026$44.75$44.95$44.73$44.9540.78K
Oct 12, 2026$45.21$45.21$44.94$45.0115.23K
Oct 9, 2026$45.11$45.22$44.94$45.157514.92K
Oct 8, 2026$44.715$44.75$44.465$44.5517.09K
Oct 7, 2026$44.96$45.0889$44.8315$45.040725.36K
Oct 6, 2026$45.74$45.7568$45.6085$45.60859.13K
Oct 5, 2026$45.29$45.5631$45.20$45.513122.72K
Oct 2, 2026$45.045$45.29$45.045$45.23578.96K
Oct 1, 2026$44.615$44.69$44.35$44.56679.85K
Sep 30, 2026$44.94$44.98$44.6494$44.649411.6K
Sep 29, 2026$44.76$44.88$44.60$44.8621.29K

Latest DNL news

The latest Smart Investors Daily articles mentioning DNL.

DNL research

Overview

Company profile and research snapshot.

Company profile

Under normal circumstances, at least 95% of the fund's total assets (exclusive of collateral held from securities lending) will be invested in component securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities. The index is a fundamentally weighted index that consists of dividend-paying global ex-U.S. common stocks with growth characteristics. The fund is non-diversified.

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

seekingalpha.com · Dec 10, 2025

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment

Denali Therapeutics Inc. is maintained at a Strong Buy rating, driven by progress in its MPS II [Hunter Syndrome] program with tividenofusp alfa. Despite discontinuing ALS efforts, DNLI's BLA for tividenofusp alfa is under FDA Priority Review under Accelerated Approval pathway, with PDUFA date extended to April 5, 2026. Company's ETV platform enables expansion into additional lysosomal storage disorders, with DNL126 for MPS IIIA offering near-term catalysts and proof of platform versatility.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.